CS
KROS icon

Credit Suisse’s Keros Therapeutics KROS Stock Holding History

Credit Suisse’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2.26M Buy
34,162
+7,520
+28% +$446K ﹤0.01% 1769
2023
Q4 		$1.06M Buy
26,642
+1,843
+7% +$57.8K ﹤0.01% 2301
2023
Q3 		$791K Sell
24,799
-2,183
-8% -$81.5K ﹤0.01% 2432
2023
Q2 		$1.08M Buy
26,982
+7,711
+40% +$338K ﹤0.01% 2334
2023
Q1 		$823K Buy
19,271
+1,878
+11% +$94.9K ﹤0.01% 2449
2022
Q4 		$835K Buy
17,393
+7,446
+75% +$348K ﹤0.01% 2463
2022
Q3 		$374K Sell
9,947
-4,268
-30% -$148K ﹤0.01% 2967
2022
Q2 		$393K Buy
14,215
+5,500
+63% +$241K ﹤0.01% 2994
2022
Q1 		$473K Buy
8,715
+896
+11% +$46K ﹤0.01% 3016
2021
Q4 		$458K Sell
7,819
-560
-7% -$27.9K ﹤0.01% 3877
2021
Q3 		$332K Buy
8,379
+12
+0.1% +$427 ﹤0.01% 4047
2021
Q2 		$356K Buy
8,367
+2,086
+33% +$113K ﹤0.01% 4026
2021
Q1 		$386K Sell
6,281
-8,932
-59% -$566K ﹤0.01% 3906
2020
Q4 		$1.07M Buy
+15,213
New +$959K ﹤0.01% 3290

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Credit Suisse's KROS Position: Q1 2024 in Review

Credit Suisse increased its Keros Therapeutics (KROS) stake by 28% in Q1 2024, buying an estimated $446K and bringing the position to 34,162 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1769.

Credit Suisse first reported a position in KROS in Q4 2020 and has held it in 14 quarters since. 147 funds tracked by Wall St. Rank hold KROS as of Q1 2024.

  • Credit Suisse held 34,162 shares of Keros Therapeutics worth $2.26M as of Q1 2024.
  • Credit Suisse bought 7,520 Keros Therapeutics shares in Q1 2024, an estimated $446K.
  • Keros Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1769 holding.
  • Credit Suisse first reported a position in Keros Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • 147 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.